Diffuse Intrinsic Pontine Glioma

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets the immune checkpoint B7-H3 for diffuse intrinsic pontine glioma, or DIPG, a rare incurable pediatric brain tumor.

The oncolytic adenovirus DNX-2401 appeared safe and feasible among a small cohort of pediatric patients with diffuse intrinsic pontine glioma, according to study results published in The New England Journal of Medicine.

Oren J. Becher, MD, has been appointed chief of the Jack Martin division of pediatric hematology-oncology at Mount Sinai Kravis Children’s Hospital.

Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for diffuse midline gliomas during the virtual American Association for Cancer Research Annual Meeting.

Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse midline glioma showed tumor regression and improvement in neurologic symptoms, according to early results of a phase 1 study.

OKN-007 received FDA fast track designation for the treatment of children with diffuse intrinsic pontine glioma, or DIPG, according to a press release from the agent’s manufacturer.

The FDA granted fast track and orphan drug designations to PTC596 for treatment of leiomyosarcoma, according to the agent’s manufacturer.

Phase 1 dose-escalation trial to determine the safety and feasibility of rapidly generated tumor multi-antigen associated specific cytotoxic T lymphocytes in patients with newly diagnosed diffuse intrinsic pontine gliomas or recurrent, progressive or refractory nonbrainstem CNS malignancies.

The FDA awarded 12 grants worth more than $15 million to fund clinical trials of medical products intended to treat patients with rare diseases.